Tulane University COVID Antibody and Immunity Network (TUCAIN)

杜兰大学新冠病毒抗体和免疫网络 (TUCAIN)

• 批准号: 10706732
• 负责人: JAMES E Robinson
• 金额: $ 43.99万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10706732
• 关键词: 2019-nCoV; Address; Advanced Development; Algorithms; Antibodies; Antibody Response; Antibody-mediated protection; Applied Research; Big Data; Blood; Blood specimen; COVID-19; COVID-19 patient; COVID-19 survivors; COVID-19 treatment; Cellular Immunity; Centers for Disease Control and Prevention (U.S.); Clinical; Clinical Data; Collection; Data; Data Set; Development; Diagnosis; Disease; Evolution; Funding; Goals; Humoral Immunities; Immune response; Immunity; Immunocompromised Host; Immunologics; Individual; Infection; Knowledge; Longevity; Louisiana; Malignant Neoplasms; Measures; Medicine; Memory; Methods; Mission; Pathogenesis; Pathogenicity; Patient-Focused Outcomes; Patients; Persons; Plasma; Recurrence; Reporting; Research; Risk; SARS-CoV-2 immunity; Serology test; Serum; Special Population; Survivors; Systems Biology; Technology; Therapeutic; Time; Universities; Vaccines; Viral; Viral Hemorrhagic Fevers; Virus; base; biobank; cell mediated immune response; cohort; convalescent plasma; coronavirus disease; human pathogen; improved; insight; longitudinal analysis; mortality; neutralizing antibody; novel; personalized medicine; prevent; programs; public health emergency; response; screening; therapeutic evaluation; treatment strategy

CD4+ T cells and B cells are critical to generate high-affinity antibodies against most pathogens, and antigen-presenting cells such as dendritic cells and macrophage are essential in delivering antigen to the lymph nodes to generate long-lived cellular and humoral immunity. As immunocompromised individuals often have deficiencies or abnormalities in one or more immune cell populations, we hypothesize that analysis of immunocompromised patients with deficiencies/abnormalities in distinct cellular compartments (eg. plasma cells in multiple myeloma; CD4+ T cells in people living with HIV; lymphocytes in chronic lymphocytic leukemia) will be able to define the role of a given immune cell type on generation of durable protective immunity against SARS-CoV-2. Moreover, these comparative analyses may further identify specific gaps in SARS-CoV-2 immunity within different immunocompromised populations that may be complemented with therapies. Through our funded U54 parent grant, we have established several cohorts of immunocompromised populations, including people living with HIV and patients with various hematologic and solid tumor cancer malignancies. In addition, we have developed a comprehensive immune analysis platform that integrates measures of cellular and humoral immunity that will allow us to perform comparative analyses of cellular and humoral immunity across multiple immunocompromised patient populations.

CD4+T细胞和B细胞是产生针对大多数病原体的高亲和力抗体的关键，而树突状细胞和巨噬细胞等抗原提呈细胞在将抗原输送到淋巴结以产生持久的细胞和体液免疫方面是必不可少的。由于免疫受损个体通常在一个或多个免疫细胞群中存在缺陷或异常，我们假设对免疫受损患者的分析在不同的细胞隔间(例如。多发性骨髓瘤中的浆细胞、艾滋病毒携带者中的CD4+T细胞、慢性淋巴细胞白血病中的淋巴细胞)将能够确定特定免疫细胞类型在产生针对SARS-CoV-2的持久保护性免疫中的作用。此外，这些比较分析可能进一步确定不同免疫受损人群中SARS-CoV-2免疫方面的具体差距，这些差距可能会得到治疗的补充。通过我们资助的U54父母基金，我们已经建立了几个免疫缺陷人群的队列，包括艾滋病毒携带者和各种血液和实体肿瘤恶性肿瘤患者。此外，我们还开发了一个全面的免疫分析平台，该平台整合了细胞和体液免疫的测量，使我们能够对多个免疫受损患者群体的细胞和体液免疫进行比较分析。